Lakewood-amedex Biotherapeutics's ROA from the second quarter of 2026 to the second quarter of and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Lakewood-amedex Biotherapeutics's ROA in the second quarter of 2026?
Lakewood-Amedex Biotherapeutics Inc. achieved a return on average assets (ROA) of 1277.21 % in its second quarter of 2026, this is above LABT's average return on assets of 0%.
Lakewood-amedex Biotherapeutics Inc. assets over the 12 months ending in its second quarter of 2026 are valued at $1 million

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector Lakewood-Amedex Biotherapeutics Inc. achieved the highest return on assets. While the total ranking for ROA unchanged, relative to the first quarter of 2026 at no. .

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	-	-	-	-	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	18	14	2	1	0
Return On Assets (TTM)	1277.21 %	8322.12 %	1816.79 %	-	-
LABT's Total Ranking	#	#	#	#	#
Total Assets (TTM) in million	5	0	0	0	0
Seq. Total Assets Change	2426.75 %	-59.24 %	-	-	-
Seq. Net Income Change	-67.29 %	932.08 %	11.79 %	-	-

LABT's 5 Years Annual ROA >> Back to LABT Management Effectiveness >> Compare LABT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	#
Sector	#
Overall	#

Return On Assets Statistics
High	Average	Low
0 %	0 %	0 %

Financial Statements
Lakewood-amedex Biotherapeutics's Assets	$ 5 million	LABT's Balance sheet
Lakewood-amedex Biotherapeutics's Income	$ 4 million	Quarterly LABT's Income Statement
LABT's Income by Division		See LABT's Income by Division

Annual Return On Assets	FY	FY	FY	FY	FY
Y / Y Total Assets Change	-	-	-	-	-
Total Assets in million	0	0	0	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	0	0	0	0	0
Annual Return On Assets	-	-	-	-	-

LABT's 5 Years Annual ROA >> Back to LABT Management Effectiveness >> Compare LABT ROA to its Competitors

More Return On Assets Ratios
LABT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LABT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LABT's Competitors
Subscribers only: Roa for Lakewood-amedex Biotherapeutics's Suppliers
Subscribers only: Return On Assets for LABT's Customers

You may also want to know
LABT's Roi	LABT's Inventory Turnover Ratio	LABT's Growth Rates	LABT's Dividend Comparisons
	LABT's Profitability Ratios	LABT's Asset Turnover Ratio	LABT's Dividend Growth
LABT's Roe	LABT's Valuation Ratios	LABT's Financial Strength Ratios	LABT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Stablecoin Development Corporation	604.72 %

Date modified: 2026-09-12T06:29:04+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.